CELL INTELLIGENCE · 肿瘤细胞治疗研究

AI 驱动的生物治疗：输血医学与生物治疗交叉领域的人工智能与信息学

AI-powered biotherapies: Artificial intelligence and informatics at the intersection of transfusion medicine and biotherapies.

AI与信息学正被定位为开启精准、数据驱动生物治疗新时代的力量。

胶质瘤中肿瘤来源的 LAIR-1 通过双重机制驱动纤维化并阻断免疫细胞招募，导致癌症免疫排斥

A dual pronged approach to cancer immune exclusion: tumor-derived LAIR-1 simultaneously drives fibrosis and blocks immune recruitment in glioma.

体内 CAR 基因治疗的前景与潜在陷阱

Promises and potential pitfalls of in vivo CAR gene therapy.

用于 CAR-T 细胞快速床旁/体内编程的可注射生物指令性微泡沫

Injectable bioinstructive microfoam for rapid bedside/in vivo programming of CAR-T cells.

促进髓系细胞活化的 CAR-T 细胞因素鉴定

Characterization of CAR-T cell factors that contribute to myeloid cell activation.

实现细胞和基因疗法的公平可及：重新思考共付费用

Toward equitable access to cell and gene therapies: rethinking co-payments.

CAR-T 细胞疗法中的 TCR：用进废退？

The TCR in CAR T cell therapy: use it or lose it?

面向新兴过继性细胞治疗的基于 PCR 的细胞动力学与生物分布分析展望

Perspectives on PCR-Based Cellular Kinetics and Biodistribution Analysis for Emerging Adoptive Cell Therapies.

CAR-T 细胞治疗在儿童、青少年和年轻成人癌症患者中的关键作用

The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer.

基因和细胞疗法的免疫原性

Immunogenicity of Gene and Cell Therapies.